Introduction
The Myb proteins comprise a family of transcription factors, characterized by their unique DNA binding domain and expression in differentiating and proliferating cells (Introna et al., 1990; Lipsick, 1996; Ness, 1996; Lipsick and Wang, 1999; Oh and Reddy, 1999) . The v-Myb transforming protein was first identified in two different avian leukemia viruses, AMV (Avian Myeloblastosis Virus) and E26. It is a truncated, mutated and constitutively expressed version of the c-Myb protein expressed in a variety of normal cells. The major translational product of the c-myb proto-oncogene is a 75 kD nuclear protein consisting of 641 amino acids, containing an N-terminal DNA binding domain, a centrally-located trans-activation domain, and a Cterminal negative regulatory domain (Ness, 1996) . The v-Myb of AMV contains a number of acquired mutations that contribute to its oncogenic activity (Weston, 1990) . Three of these mutations lie within the highly conserved DNA binding domain and have proved to be important for the interactions between Myb and other regulatory proteins (Ness, 1996) .
Although derived from the chicken c-myb gene, the biological effects of v-Myb are strikingly different from that of c-Myb. The c-myb gene is highly expressed in immature, proliferating hematopoietic cells and its expression declines as cells undergo terminal differentiation, suggesting that the c-Myb protein plays an important role in hematopoietic cell differentiation and proliferation (Mucenski et al., 1991) . While the product of the normal c-myb gene has little or no transforming activity (Todokoro et al., 1988; Gonda et al., 1989) , over-expression of v-Myb transforms immature, cytokine-dependent hematopoietic cells in culture and induces acute leukemias in animals (Lipsick and Wang, 1999) . These observations have led to a conclusion that v-Myb type mutations are required to reveal its oncogenic activity. However, the mechanisms by which these mutations convert c-Myb to a stronger transforming protein are unknown.
In normal cells, the transcriptional activity of c-Myb is likely to be regulated by upstream signaling pathways (Dash et al., 1996) . Several distinct regulatory mechanisms have been shown to affect c-Myb protein activity (Leverson and Ness, 1998; Winn et al., 2003; Lei et al., 2005) . However v-Myb is able to escape such regulation via mutations and truncations. A model has been developed, in which cMyb activity is auto-inhibited or negatively regulated while the mutated and oncogenic v-Myb is constitutively activated. In this view, the activities of c-Myb and v-Myb are similar and the differences between them are quantitative in nature. Thus, the de-regulated v-Myb is equivalent to a higher level of activity of c-Myb.
There is also evidence suggesting that the differences between c-Myb and v-Myb are qualitative in nature, and that v-Myb has a very different transcriptional specificity than c-Myb. For example, the DNA binding domain of AMV v-Myb contains three amino acid substitutions that are responsible for its altered ability to regulate at least two chicken genes: mim-1 and gbx2 (Ness et al., 1989; Kowenz-Leutz et al., 1997) . The mim-1 gene promoter contains three Myb binding sites and, when fused to a reporter gene and tested in transfection assays, can be activated by c-Myb or v-Myb. However, v-Myb is unable to activate the endogenous, chromosomal mim-1 gene, due to the effects of a Myb-specific upstream enhancer (Chayka et al., 2005) . In contrast, ectopic expression of AMV v-Myb stimulates the expression of the endogenous gbx2 gene which c-Myb is unable to activate. The results using endogenous target genes contradict the results obtained with plasmid reporter genes and suggest that mutations in v-Myb alter its transcriptional specificity.
Although the DNA binding domain mutations have been shown to affect the ability of v-Myb to regulate the mim-1 and gbx2 genes, v-Myb also has a number of other mutations that distinguish it from c-Myb, including N-and C-terminal deletions and additional amino acid substitutions in the transcriptional activation domain, many of which have been implicated in the transforming activity of v-Myb (Frykberg et al., 1988; Introna et al., 1990; Gra¨sser et al., 1992; Dini et al., 1995; Fu and Lipsick, 1996; Leverson and Ness, 1998) . To address the roles of the v-Myb mutations in transcriptional regulation, we combined structure-function studies of v-Myb and c-Myb with microarray-based transcription assays that detected changes in endogenous gene activation. The results suggest that v-Myb and c-Myb have overlapping but qualitatively distinct transcriptional activities and that each one of the vMyb mutations contributes to its unique activity. The transcriptional specificities of v-Myb and c-Myb appear to be complex and can be affected by many different parts of the proteins.
Results
The DNA binding domain mutations in v-Myb affect transcriptional specificity but not DNA binding activity Three point mutations in the AMV v-Myb DNA binding domain (I91N, L106H and V117D) prevent v-Myb from activating the chicken mim-1 gene (Ness et al., 1989; Introna et al., 1990) . However, in transfection experiments, v-Myb and c-Myb activate most reporter gene constructs similarly, suggesting that the key difference between the products of the protooncogene and the oncogene was measurable only on native genes, not reporter gene constructs. As a starting point for investigating the activity of v-Myb in more detail, we first addressed whether introducing the three v-Myb DNA binding domain mutations, in the absence of any other v-Myb specific changes, would also change the specificity of wild type c-Myb. Sitedirected mutagenesis was used to introduce one, two or all three DNA binding domain mutations into an expression vector encoding c-Myb (Figure 1a ). An electrophoretic mobility shift assay was used to compare the DNA binding activities of the wild type and mutant proteins, and the results showed that wild type c-Myb, v-Myb and the mutant constructs were able to bind the high-affinity Myb binding site from the mim-1 gene promoter with similar efficiencies (Figure 1b and data not shown). The binding was efficiently competed by excess specific but not nonspecific oligonucleotides and could be super-shifted using anti-Myb antibodies (data not shown). These results agree with several published studies showing that c-Myb and v-Myb have similar in vitro DNA binding activities (Ness et al., 1989; Leverson and Ness, 1998; Rushton and Ness, 2001) . In transient transfection assays, each of the Myb proteins strongly activated a reporter gene construct containing several Myb binding sites cloned upstream of a minimal promoter driving expression of luciferase as well as other reporter genes containing Myb-regulated promoters (e.g. mim-1; data not shown). Thus, the proteins were indistinguishable in two standard assays used to compare transcription factors, activation of reporter genes and in vitro DNA binding.
An endogenous gene activation assay was used to test the transcriptional specificities of the constructs. Briefly, plasmids expressing each of the Myb constructs diagrammed in Figure 1a were transfected into HD-11 cells, chicken macrophage cells that lack c-Myb and mim-1 expression but are related to the myeloblasts transformed by v-Myb. Ectopic expression of c-Myb is sufficient to activate the endogenous mim-1 gene in HD-11 cells, and this has been used as a standard assay for comparing the activities of various Myb proteins and the effects of regulators on the activities of c- Myb and v-Myb (Dash et al., 1996; Leverson and Ness, 1998; Lei et al., 2004 Lei et al., , 2005 . As shown in Figure 1c , expression of c-Myb (lane 2) or the c-Myb/ v-Myb recombinant CCA that lacks the DNA binding domain mutations (lane 7) resulted in activation of the endogenous mim-1 gene, as detected by Northern blotting of RNAs from the transfected cells. The 1MutC construct, containing only the I91N mutation from v-Myb, was also able to activate the mim-1 gene (lane 3). However, the mim-1 gene was not induced in cells transfected by expression vector alone (lane 1) or by plasmids expressing the 2MutC, 3MutC or v-Myb constructs (lanes 4-6). Western blotting (not shown) confirmed that all the proteins were expressed at similar levels. Thus, although introduction of the DNA binding domain mutations from v-Myb into c-Myb had little or no effect on the ability to bind DNA or to activate the mim-1 promoter in the context of a reporter gene assay, the mutations did affect c-Myb specificity and prevented it from activating the endogenous, chromosomal mim-1 gene. Based on these results, we conclude that the three v-Myb-specific DNA binding domain mutations affect the specificity of c-Myb, at least on some target genes.
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Mutations in v-Myb have dramatic effects on its specificity Next, we utilized a microarray approach (Rushton et al., 2003; Lei et al., 2004) to compare the specificities of v-Myb and c-Myb and to determine whether the differences observed in the mim-1 gene assay were typical of other Myb-regulated genes. Briefly, recombinant adenovirus vectors were used to ectopically express c-Myb, v-Myb or the 3MutC construct (c-Myb with the three v-Myb DNA binding domain mutations, Figure 1a ) in human MCF-7 cells, a mammary cell line that expresses Myb proteins following estrogen receptor stimulation (Hodges et al., 2003) . This virus vector/cell line combination has been extremely useful for characterizing the activities of different Myb proteins in human cells (Rushton et al., 2003; Lei et al., 2004) . The viruses coexpressed GFP, which was used to assess the efficiency of infection and Myb protein expression was monitored by Western blotting (Figure 2a) . After 16 h, RNA was isolated and changes in gene expression were determined using Affymetrix microarrays. The entire experiment was conducted twice, and the data were analysed to identify the genes that were reproducibly up-or down-regulated at least twofold as a result of expressing one of the Myb proteins. The analysis identified 172 and 94 genes that were affected by expression of c-Myb or v-Myb, respectively. However, as shown in the Venn diagram analysis in Figure 2b , c-Myb and v-Myb affected overlapping, but distinct sets of genes, suggesting that they had different transcriptional specificities. The changes in gene expression for 44 of the most strongly regulated genes, as well as actin as an unaffected 'housekeeping' gene control, are summarized in Figure 2c , where each column is a different RNA sample, each row is a different gene and blue and red shading indicate down-and up-regulation, relative to the average of two control virus-infected samples, respectively. Some genes (e.g. CTNNAL1, ISG20, PPM1E) were regulated similarly by c-Myb, v-Myb and the 3MutC protein. However, most of the affected genes were regulated differently by c-Myb and v-Myb. For example, the DHRS2, SAT, MT1H and KRT16 genes were strongly upregulated by c-Myb and 3MutC, but were unaffected by v-Myb. In contrast, the FABP5 and FOXD1 genes were strongly activated by v-Myb but were refractory to c-Myb or 3MutC. The CXCR4 gene was much more strongly activated by v-Myb than by c-Myb, but NAB2, MAPK3, FOSL2 and TNFRSF21 were all downregulated by v-Myb and either unaffected or weakly upregulated by c-Myb and 3MutC.
To validate the microarray results, the expression of some Myb-regulated genes were also assessed by Northern blotting. As shown in Figure 3a , the FABP5 gene was upregulated only by v-Myb, the CTNNAL1 gene was upregulated by all three Myb proteins and the TGFB1 and DHRS2 genes were upregulated by c-Myb and 3MutC but not v-Myb. We also validated the ability of v-Myb, but not c-Myb, to strongly induce the human CXCR4 gene, which encodes the receptor for C-X-C chemokines or SDF-1. MCF-7 cells were infected with RNA samples prepared from chicken HD-11 cells transfected with control vector or plasmids expressing c-Myb, 1MutC, 2MutC, 3MutC, v-Myb or CCA (lanes 1-7, respectively) were assayed by Northern blotting using a probe specific for the Myb-regulated mim-1 gene. The blot was stripped and re-hybridized with a probe for beta-actin as an RNA loading control.
Qualitative differences between c-Myb and v-Myb F Liu et al adenovirus vectors expressing GFP only or GFP plus c-Myb or v-Myb. After 16 h, RNA was isolated and the CXCR4 gene expression was monitored using triplicate real-time PCR assays and was normalized to the expression of GAPDH. As shown in Figure 3b , the expression of c-Myb led to an approximately twofold induction of CXCR4 expression, but v-Myb expression induced the CXCR4 gene more than 10-fold, confirming the microarray results. We have not validated the results for all the genes detected in our microarray assays, but these and previously published studies (Rushton et al., 2003; Lei et al., 2004) have consistently shown that genes that are shown to be strongly and reproducibly up-or down-regulated in microarray assays show similar expression changes when assayed using other methods such as real-time PCR or Northern blots.
The results in Figures 2 and 3 suggest that c-Myb and v-Myb have dramatically different transcriptional specificities. Thus, the mutations in v-Myb appear to do much more than just inactivate negative regulatory mechanisms, they also change the spectrum of genes that v-Myb is capable of regulating. The results show that the 3MutC construct is much more similar to c-Myb than to v-Myb. Thus, most of the differences in transcriptional specificity may be due to mutations outside the v-Myb DNA binding domain.
c-Myb and v-Myb also have distinct activities in myeloid cells
The microarray experiments described in Figure 2 were performed with MCF-7 cells that express c-Myb after estrogen stimulation but are not a target of transformation by v-Myb. To rule out any possibility that the observed differences in c-Myb and v-Myb activity were MCF-7 cell-specific, we compared the activities of c-Myb and v-Myb in primary human monocytes. We chose these cells because they lack any detectable expression of c-Myb or v-Myb but are closely related to the myeloid cells transformed by v-Myb. By using human instead of chicken cells, we could take advantage of the much better characterized human genome and After 16 h, total RNA was isolated and gene expression patterns were analysed using Affymetrix U133A microarrays. The entire experiment was performed twice and the replicates were used to identify genes that were expressed above background levels and that were reproducibly up-or downregulated at least twofold following expression of c-Myb or v-Myb. Qualitative differences between c-Myb and v-Myb F Liu et al associated annotation. Finally, using primary cells allowed us to avoid any complications from other oncogenes that might be activated in cell lines. Briefly, human peripheral blood monocytes were isolated from whole blood buffy coat preparations then either mock infected or infected by control adenovirus or adenovirus vectors expressing c-Myb or v-Myb. Infection was monitored by GFP expression and Myb protein expression was monitored by Western blotting (Figure 4a) . After 16 h, RNA was isolated and changes in gene expression were assessed using Affymetrix microarrays. The entire experiment was repeated twice, using monocytes from different donors, and the data were analysed to identify genes that were reproducibly up-or downregulated at least twofold by either c-Myb or v-Myb, compared to the cells infected by control virus. The results showed that over 1500 genes were up-or downregulated by either c-Myb or v-Myb, but only 106 genes were affected by both. The Venn diagram in Figure 4b summarizes the data for the genes that were reproducibly upregulated by c-Myb (312 genes) or v-Myb (355 genes). Only 24 genes were upregulated by both c-Myb and v-Myb in human monocytes. The gene expression data for 82 representative genes are summarized in Figure 4c , where each column is a different RNA sample, each row is a different gene and the genes that were up-or down-regulated are indicated by red or blue shading, respectively. Despite the fact that v-Myb only differs from c-Myb by N-and Cterminal truncations and 11 amino acid substitutions, the two proteins had dramatically different activities on gene expression. Expression of c-Myb led to upregulation of two previously identified Myb-regulated genes encoding the oxytocin receptor (OXTR) and cyclin A1 (CCNA1) (Inoue et al., 1994; Muller et al., 1999) as well as several genes encoding cytokines (IL12B, IL23A and IL6) and the gene encoding the tumor-associated antigen TM4SF1/L6, none of which were strongly activated by v-Myb. In fact, expression of v-Myb led to downregulation of many of the genes that were upregulated by c-Myb, almost as if the activities of c-Myb and v-Myb were opposite. Thus, in these microarray based assays of Myb protein transcriptional activity, which used changes in the expression of endogenous genes as indicators of transcription factor activity, the v-Myb and c-Myb proteins had distinct and nearly nonoverlapping activities, suggesting that the oncogenic mutations in v-Myb had dramatically altered its transcriptional specificity.
To partially validate the microarray data shown in Figure 4 , we performed real-time PCR analysis to independently assess the changes in gene expression for three representative genes, one that was induced by c-Myb but repressed by v-Myb (IL12B), one that was activated strongly by c-Myb but only weakly by v-Myb (CCNA1) and one that was induced only by v-Myb (LIPA). As shown in Figure 5a , the results of the realtime PCR analysis closely paralleled the microarray results, confirming that v-Myb and c-Myb had distinct effects on gene expression.
We also investigated whether c-Myb and v-Myb regulated similar genes in the MCF-7 and monocyte cell systems. Probe sets for 910 of the more than 1500 monocyte genes that were up-or down-regulated following expression of c-Myb or v-Myb were also present on the older GeneChips used for the MCF-7 experiments. The Venn Diagram in Figure 5b compares the 910 genes that were affected by c-Myb and v-Myb in monocytes to the 235 genes that were affected in MCF-7 cells and shows that only 28 genes were either up-or down-regulated in both cell types. The microarray results for those 28 genes are summarized in Figure 5c . Only seven genes, including CXCR4 and CTNNAL1, Qualitative differences between c-Myb and v-Myb F Liu et al were upregulated by both c-Myb and v-Myb in both cell types (top group). A group of 13 genes, including the SRRM2, CLIC4 and CRIM1 genes, were regulated in opposite directions in the two cell types (bottom group). The remaining genes were affected differentially depending on the cell type and Myb protein used. These results are similar to our published results showing that different Myb proteins regulate nearly nonoverlapping sets of genes in different types of human cells (Rushton et al., 2003; Lei et al., 2004) and suggest that c-Myb and v-Myb cooperate with tissue-specific co-factors or transcription factors to regulate different genes in different cell types (Ness and Engel, 1994; Ness, 2003) .
Subsets of target genes are affected by specific v-Myb mutations
We constructed a series of recombinants between v-Myb and c-Myb (Figure 6a ) and used them to map the differences that were responsible for the distinct transcriptional activities of the two proteins. In transfection experiments, all the recombinants were expressed at similar levels and all were able to activate Mybresponsive reporter genes similarly to c-Myb (data not shown). The reporter gene assays did not distinguish the recombinants, but showed that all were able to bind DNA and stimulate transcription. Next, we assessed the specificity of the recombinants by testing their abilities to activate a series of endogenous target genes. Recombinant adenoviruses expressing each construct were prepared and used to express the proteins in chicken HD-11 cells or human MCF-7 cells. After 16 h, RNA was isolated and analysed by Northern blotting or real-time PCR. Figure 6b shows the results for the well-characterized chicken mim-1 gene, which was activated by all the constructs except v-Myb and 3MutC, a variant of c-Myb containing the three v-Myb specific DNA binding domain mutations. Thus, neither the N-nor C-terminal deletions or the other mutations in v-Myb had any effect on the ability to activate the mim-1 gene, which was uniquely sensitive to the DNA binding domain mutations.
In contrast, as shown in Figure 6c , the presence or absence of the DNA binding domain mutations had no effect on the ability of the various constructs to activate two human genes, DHRS2 and FABP5, which had been identified in the microarray assays shown in Figure 2 . The DHRS2 gene was strongly induced by all the constructs with the exception of v-Myb, which was unable to stimulate expression of the gene above background levels. However, both v-Myb and the CCA recombinant were able to stimulate expression of the FABP5 gene, which was not stimulated by the other constructs. The ability to activate the FABP5 gene was not affected by the DNA binding domain mutations that affected activation of the mim-1 gene. Instead, activation of FABP5 expression was limited to the constructs that were truncated at the C-terminus and contained all the other v-Myb mutations in the transcriptional activation domain.
The expression of the DHRS2 gene, and another target gene CXCR4, were assayed using real-time PCR. As shown in Figure 6d , the DHRS2 gene was stimulated 12-20-fold by c-Myb and the NdC and Cdc constructs, about 5-10-fold by the 3MutC, CCA and CX constructs, but was not significantly stimulated by v-Myb. In contrast, v-Myb was the most active at stimulating the CXCR4 gene (10-fold), which was also strongly activated by the Cdc construct but only weakly activated by c-Myb, 3MutC, CCA and CX and not significantly activated by NdC. We obtained similar data for target gene ABCC3 (not shown), which was activated by c-Myb, 3MutC, Cdc, CCA and CX, but not by Ndc or v-Myb. These results lead to an important conclusion: The oncogenic v-Myb protein is not more active than cMyb. Instead, it has a qualitatively different activity. Each type of Myb protein has a unique transcriptional activity and each mutation that distinguishes v-Myb from c-Myb changes its activity when measured using native target genes.
The results of these assays are summarized in Figure 7 , which shows the regions of c-Myb and v-Myb that affect the activation of specific target genes. Based on these results, we conclude that the transcriptional specificities of c-Myb and v-Myb are controlled by several domains in the protein, including the N-terminus, DNA binding domain, transcriptional activation domain and Cterminal domain. Furthermore, mutations in specific domains affect individual subsets of target genes. The results suggest that v-Myb has acquired a number of different mutations, each of which has an effect on its transcriptional specificity. The combined influences of all the mutations lead to the marked differences in specificity observed in the microarray assays shown in Figures 2 and 4 .
Discussion
We report results that lead to an important and dramatic conclusion: the mutations that increase the Qualitative differences between c-Myb and v-Myboncogenic activity of v-Myb also have qualitative effects on its transcriptional specificity. Using microarray approaches in human cells, the data in Figures 2 and 4 show that the normal c-Myb protein has a dramatically different transcriptional activity than the oncogenic v-Myb protein derived from it. The observed activities were equally distinct whether mammary epithelial cells or primary myeloid cells were used in the assays, suggesting that the differences were due to inherent properties of the Myb proteins themselves and not celltype specific mechanisms. In each case some of the microarray results were validated by using Northern blots or real-time PCR to follow changes in the expression of representative genes. These results are consistent with the known differences in the abilities of v-Myb and c-Myb to activate the chicken genes mim-1 and gbx-2 (Ness et al., 1989; Dash et al., 1996; KowenzLeutz et al., 1997) and suggest that relatively minor mutations can completely change the specificities of transcription factors like c-Myb and v-Myb.
Our data do not address whether the genes we identified are directly or indirectly regulated by Myb proteins. However, several of the genes identified in our assays, such as the genes encoding cyclin A1, CSF2 and the oxytocin receptor (Szczylik et al., 1993; Inoue et al., 1994; Muller et al., 1999) have been shown by other laboratories to be regulated by c-Myb or to have Myb binding sites in their promoters. The genes we identified did not overlap with Myb-regulated genes identified in lymphoid cells (Lang et al., 2005) . Indeed, comparing the genes that were affected in MCF-7 cells and monocytes showed very little overlap, consistent with our previously published results (Lei et al., 2004) . Thus, c-Myb and v-Myb appear to be able to regulate completely different sets of genes in different cell types. Our preliminary characterization of the promoters for the KRT16, DHRS2 and CXCR4 genes (unpublished results) have identified Myb binding sites and have shown that the promoters can be activated by Myb proteins in transfection experiments, so we expect that many of the genes identified in our microarray assays are directly regulated by Myb proteins binding to their promoters. However, Myb proteins can activate genes through direct as well as indirect mechanisms (Travali et al., 1991; Plaza et al., 1995; Sun-Hoffman et al., 1996; Tanno et al., 2002) , so the true activities of transcription factors like c-Myb and v-Myb are the sums of their direct and indirect effects. For the purposes of comparing the activities of the c-Myb and v-Myb transcription factors, it is more relevant to assess their total activities using an unbiased approach such as a microarray assay than to focus only on the genes that are directly regulated via Myb binding sites in their promoters.
The differences between c-Myb and v-Myb were extremely interesting. For example, in MCF-7 cells, v-Myb caused specific upregulation of the chemokine receptor CXCR4 (10-fold), which can stimulate the proliferation of MCF-7 cells, the Forkhead transcription factor FOXD1 (threefold), involved in cell cycle control, and Fatty Acid Binding Protein-5 (FABP5, fourfold), an indicator of proliferation in epithelial cells. In primary monocytes, c-Myb activated genes associated with both proliferation and differentiation such as cyclin A1 (CCNA1, fivefold), oxytocin receptor (OXTR, fivefold), IL6 (3-5-fold) and IL12B (11-17-fold). Thus, many of the genes affected by c-Myb or v-Myb are involved in growth control, differentiation or apoptosis.
Our results comparing the specificities of c-Myb proteins supplemented with various v-Myb mutations showed that several different parts of the c-Myb protein are involved in controlling transcriptional specificity. For example, the N-terminal domain of c-Myb, which v-Myb lacks, was required for activation of the ABCC3 gene, consistent with previous reports suggesting that the N-terminal domain of c-Myb could allow it to interact with additional promoters that are not recognized by v-Myb (Dini and Lipsick, 1993) . However, our results showed that the other mutations in v-Myb also affected the activation of specific genes, and that no single mutation was responsible for the dramatic differences observed between v-Myb and c-Myb, suggesting that transcriptional specificity is a complex Figure 6 . The columns at right indicate whether the indicated Myb protein was able ( þ ) or unable (À) to activate the indicated genes. The regions of v-Myb and c-Myb containing determinants for regulating specific genes are indicated by labels at the bottom of the figure.
Qualitative differences between c-Myb and v-Myb F Liu et al function controlled by several parts of the protein. A number of reports have shown that mutations in transcriptional activation domains can alter the specificities of transcription factors (Hou et al., 1997; Epstein et al., 1998; Butz et al., 2004; Chen and Bieker, 2004; Kouskouti et al., 2004; Lei et al., 2004; Takahashi et al., 2005) . These results imply that transcription factors like c-Myb and v-Myb interact with a large collection of different co-factors to regulate different genes, or interact with co-factors in qualitatively different ways, leading to the regulation of different sets of target genes.
Our results raise several important issues for further study. First, c-Myb is known to undergo a number of post-translational modifications including phosphorylation, ubiquitinylation, acetylation and sumoylation that may mimic some of the mutational differences between c-Myb and v-Myb. Particular post-translational modifications may alter the transcriptional activity of c-Myb allowing it to regulate specific genes in appropriate situations or in response to signaling pathways. The mutations in v-Myb may allow it to mimic a specifically modified and targeted version of c-Myb. Second, our results suggest that transcription factors interact with a large variety of different co-factors or with different parts of the transcriptional machinery that allow their activities to be complex and diverse. The identification of those components will be a necessary step in furthering our understanding of the mechanisms involved in specific gene regulation by transcription factors like c-Myb and v-Myb.
Materials and methods

Cells and tissue culture
All media, buffers and related tissue culture reagents were obtained from Gibco/Invitrogen (Carlsbad, CA, USA). Dulbecco's Modified Eagle Medium was supplemented with 100 U/ml of penicillin, 100 mg/ml of Streptomycin, 10 mM HEPES (pH 7.2) and 100 mM MEM nonessential amino acids. For MCF-7 and 293 cells, the medium was supplemented with 10% fetal bovine serum (FBS). For HD-11 cells, the medium was supplemented with 8% FBS and 2% heat-inactivated chicken serum. Human monocytes were isolated from buffy coat blood samples purchased from United Blood Services (Albuquerque, NM, USA) using Ficoll-Paque Plus (Amersham, Uppsala, Sweden). The purified cells were washed twice with Hank's balanced salt solution and once with cold phosphate buffered saline supplemented with 0.5% FBS and 2 mM EDTA. CD14 þ monocytes were purified by negative selection using the Monocyte Isolation Kit II (Miltenyi Biotec, Auburn, CA, USA) and were cultured in RPMI 1640 medium supplemented with 10% FBS.
Plasmid constructions
Chicken c-Myb and v-Myb cDNAs were cloned in pCDNA3 expression vectors (Invitrogen, Carlsbad, CA, USA). The NdC deletion construct was generated by using primers 5 0 -AA CAGGATCCATGGAAACCGTCATAAAGAATAGAACA GATGTTCAGTGCCAGCA-3 0 and 5 0 -CAGGCCGGCTTT GGAGGACT-3 0 with a c-Myb template to yield the truncated N-terminal end. The resulting PCR fragment was digested with BamH1 and EcoR1 and ligated into a c-Myb expression construct digested with the same restriction enzymes. The domain swaps of Cdc and CCA were constructed by exchanging fragments between c-Myb and v-Myb after digestion with HincII/Xbal or BamH1/EcoR1, respectively. The CX deletion construct has been described previously (Lei et al., 2004) . To make the 3MutC construct, the DNA binding domain of chicken c-Myb was sub-cloned using BamH1 and EcoRI sites into vector pGEM4 (Promega, Madison, WI, USA). The three mutations (I91N, L106H and V117D) were introduced using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using the following primers (mismatched nucleotides are underlined):
TATTAAACCCAGAACTTAACAAAGGT CCATGGACTAAAGA I91N LOW: TCTTTAGTCCATGGACCTTTGTTAAGT TCTGGGTTTAATA L106H TOP: ATCAAAGGGTAATAGAACACGTGCAG AAATACGGTCCA L106H LOW: TGGACCGTATTTCTGCACGTGTTCTAT TACCCTTTGAT V117D TOP: CAAAGCGCTGGTCGGACATTGCTAAG CATTTGA V117 LOW: TCAAATGCTTAGCAATGTCCGACCAG CGCTTTG After the mutagenesis, the DNA binding domain was cloned back to the c-Myb cDNA in pCDNA3 (Invitrogen, Carlsbad, CA, USA) with the same restriction sites. All PCR was performed using high fidelity polymerase Pfu (Stratagene, La Jolla, CA, USA), and all the constructs were verified through nucleotide sequencing. To prepare adenovirus vectors, the cDNAs of chicken c-Myb, v-Myb and various mutants were transferred to the shuttle vector pAdTrackCMV and recombined with pAdEasy as described (Lei et al., 2004) . Electrophoretic mobility shift assays were performed using nuclear extracts from 293 cells transfected with empty vector or vectors expressing c-Myb or 3MutC and radiolabeled oligonucleotide probes containing a high affinity Myb binding site, as described previously (Ness et al., 1989; Ness et al., 1993; Dash et al., 1996; Leverson and Ness, 1998) .
Microarray assays
Gene expression in adenovirus-transduced cells was analysed by microarray assays as described previously (Rushton et al., 2003; Lei et al., 2004) . Briefly, infections were adjusted to maximize the expression of Myb protein expression (measured by Western blotting) and the efficiency of infection (measured by GFP expression). Cells were collected 16 h after infection and total RNA was purified using RNeasy mini kits (Qiagen, Valencia, CA, USA). RNA quality was monitored using the Bioanalyser 2100 (Agilent, Palo Alto, CA, USA). Preparation of double stranded cDNA, biotin-labeled cRNA and hybridization to Affymetrix GeneChips was performed exactly as suggested by the manufacturer (Affymetrix, Santa Clara, CA, USA). The microarray data were scaled to an average fluorescence value of 500 using Affymetrix GCOS software 5.0. The data were normalized to the average of the control samples and up-or down-regulated genes were identified using GeneSpring 7.2 (Silicon Genetics, Redwood City, CA, USA). Additional data is available in the Supplementary Tables or by contacting the authors (SAN). The MCF-7 and monocyte microarray data has been deposited in the NCBI GEO database (http://www.ncbi.nlm.nih.gov/geo/) and is available Qualitative differences between c-Myb and v-Myb F Liu et al using GEO series identifiers GSE2815 and GSE2816, respectively.
Protein and RNA expression assays Western blotting with Myb-specific antibodies was used to monitor Myb protein expression as described previously (Dash et al., 1996; Leverson and Ness, 1998) . Northern blot analysis of gene expression was performed using 10 mg of total RNA (Lei et al., 2004) . For real-time PCR, total RNA (1 mg) was converted to cDNA using the SuperScript III First-Strand kit (Invitrogen, Carlsbad, CA, USA), then 2% of the resulting product was used for each 20 ml real-time PCR reaction using commercially available probes (Applied Biosystems, Foster City, CA, USA). The results were normalized to the levels of GAPDH expression, which was assayed in parallel.
